Literature DB >> 2368958

Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma.

M C Liu1, E R Bleecker, L M Lichtenstein, A Kagey-Sobotka, Y Niv, T L McLemore, S Permutt, D Proud, W C Hubbard.   

Abstract

Histamine and certain cyclooxygenase products of arachidonic acid have been implicated as mediators of inflammation and are potent constrictors of human airways. Because asthma may represent manifestations of chronic inflammation of the airways, the levels of histamine and six prostanoid mediators were measured in airway fluids obtained by bronchoalveolar lavage (BAL) of 12 normal, 11 allergic rhinitic, and 15 asymptomatic, allergic asthmatic subjects. Simultaneous profiling of prostanoid mediators in individual samples was performed using gas chromatography-mass spectrometry. Levels of PGD2, 9 alpha,11 beta-PGF2 and PGF2 alpha were 12 to 22 times higher in asthmatic than in normal subjects (p less than 0.01), with concentrations in airway fluids of asthmatic subjects after correction for dilution of 3.8, 0.5, and 1.4 nanomolar, respectively. Levels of PGD2 and 9 alpha,11 beta-PGF2 were increased nearly tenfold in asthmatic subjects compared with those in rhinitic subjects (p less than 0.01), distinguishing the subjects with lower airway disease from those with another atopic condition. Histamine levels were increased fourfold in asthmatic subjects compared with those in normal subjects (p less than 0.001); however, similar increases were found in rhinitic subjects. We conclude that elevated levels of multiple mediators with potent bronchoconstricting activity are present in the airways of subjects with mild asthma, indicating that even mild disease is associated with evidence of airway inflammation. The interactions of bronchoconstricting mediators and airway inflammation may play important roles in the pathogenesis of asthma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2368958     DOI: 10.1164/ajrccm/142.1.126

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  48 in total

1.  Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis.

Authors:  P M van Grunsven; C P van Schayck; J Molema; R P Akkermans; C van Weel
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 2.  Pharmacologic management of the hospitalized pediatric asthma patient.

Authors:  K A Hardin; H J Kallas; R J McDonald
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

3.  Effect of inhaled prostaglandin D2 in normal and atopic subjects, and of pretreatment with leukotriene D4.

Authors:  S E Sampson; A P Sampson; J F Costello
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

4.  Inhibition of calcium-independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium.

Authors:  Prerna Rastogi; Jane McHowat
Journal:  Respir Physiol Neurobiol       Date:  2008-11-18       Impact factor: 1.931

5.  Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.

Authors:  Marco Idzko; Hamida Hammad; Menno van Nimwegen; Mirjam Kool; Nanda Vos; Henk C Hoogsteden; Bart N Lambrecht
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

6.  Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.

Authors:  Kathryn L Pothoven; James E Norton; Kathryn E Hulse; Lydia A Suh; Roderick G Carter; Erin Rocci; Kathleen E Harris; Stephanie Shintani-Smith; David B Conley; Rakesh K Chandra; Mark C Liu; Atsushi Kato; Nirmala Gonsalves; Leslie C Grammer; Anju T Peters; Robert C Kern; Paul J Bryce; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-04-01       Impact factor: 10.793

7.  Cross-talk between human mast cells and bronchial epithelial cells in plasminogen activator inhibitor-1 production via transforming growth factor-β1.

Authors:  Seong H Cho; Sun H Lee; Atsushi Kato; Tetsuji Takabayashi; Marianna Kulka; Soon C Shin; Robert P Schleimer
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

8.  Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma.

Authors:  J A Schmidt; F M Bell; E Akam; C Marshall; I A Dainty; A Heinemann; I G Dougall; R V Bonnert; C A Sargent
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

9.  Use of high-resolution metabolomics for the identification of metabolic signals associated with traffic-related air pollution.

Authors:  Donghai Liang; Jennifer L Moutinho; Rachel Golan; Tianwei Yu; Chandresh N Ladva; Megan Niedzwiecki; Douglas I Walker; Stefanie Ebelt Sarnat; Howard H Chang; Roby Greenwald; Dean P Jones; Armistead G Russell; Jeremy A Sarnat
Journal:  Environ Int       Date:  2018-08-07       Impact factor: 9.621

10.  Histamine, carbachol, and serotonin induce hyperresponsiveness to ATP in guinea pig tracheas: involvement of COX-2 pathway.

Authors:  Luis M Montaño; Verónica Carbajal; Mario H Vargas; Luz M García-Hernández; Verónica Díaz-Hernández; Marco Checa; Carlos Barajas-López
Journal:  Pflugers Arch       Date:  2013-03-10       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.